Novartis Ag

Boost for cheaper drugs: SC rejects Novartis patent on Glivec

A decision in the seven-year legal battle is keenly awaited by the two most interested parties- big pharma companies and health aid groups - with both sides saying the outcome will set a precedent with far-reaching consequences for the future availability of the drugs.

Novartis Q4 net dips 3 percent at Rs 33 cr

For the year ended 31 March 2012, the company posted a net profit of Rs 152.02 crore, as against Rs 146.67 crore in 2010-11 fiscal.

9 things that could move the market today

US credit-worthiness is on slippery ground. Weak start to Asian markets could be a drag on sentiment and the petrol price hike is likely to fuel inflation in the coming months.

Novartis vs India: the case that could change cheap medicine

Western firms see huge potential in India's rapidly growing economy but are wary of lax protection for intellectual property. They argue India is failing to recognise valuable medical innovation.